Figure 2.
piRNA-30473 inhibition decreases the tumorigenesis of DLBCL. (A) SU-DHL-8 cells (antagomir-NC or antagomir-30473 transfected) were harvested at 24, 48, and 72 hours after transfection. Cell proliferation was assessed by CCK-8 assays. (B-C) Cell cycle distribution of control and piRNA-30473-depleted SU-DHL-8 cells indicated by DNA content index. (D) Percentage of apoptotic cells in control and piRNA-30473-depleted SU-DHL-8 cells. (E) Schematic illustration of the DLBCL mouse model treated with antagomir-30473 or PBS in vivo injection. (F) DLBCL mice were treated with antagomir-30473 or PBS. Tumor volumes were monitored every other day. Error bars represent the mean ± standard deviation (SD) of 5 independent experiments. ***P < .001; ****P < .0001.

piRNA-30473 inhibition decreases the tumorigenesis of DLBCL. (A) SU-DHL-8 cells (antagomir-NC or antagomir-30473 transfected) were harvested at 24, 48, and 72 hours after transfection. Cell proliferation was assessed by CCK-8 assays. (B-C) Cell cycle distribution of control and piRNA-30473-depleted SU-DHL-8 cells indicated by DNA content index. (D) Percentage of apoptotic cells in control and piRNA-30473-depleted SU-DHL-8 cells. (E) Schematic illustration of the DLBCL mouse model treated with antagomir-30473 or PBS in vivo injection. (F) DLBCL mice were treated with antagomir-30473 or PBS. Tumor volumes were monitored every other day. Error bars represent the mean ± standard deviation (SD) of 5 independent experiments. ***P < .001; ****P < .0001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal